ClinicalTrials.Veeva

Menu

Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury

Q

Qianfoshan Hospital

Status

Active, not recruiting

Conditions

AKI

Study type

Observational

Funder types

Other

Identifiers

NCT06596798
LCYX-LX-20240102

Details and patient eligibility

About

In this study, the investigators aim to develop a risk prediction model for acute kidney injury (AKI) in hospitalized patients using the calcineurin inhibitor tacrolimus. This will be achieved by mining electronic medical record data and employing explainable deep learning methods. The model will provide clinical decision support for timely intervention and treatment. Compared to traditional machine learning models, deep neural networks can extract more nuanced features from complex medical data and perform more precise pattern recognition, thereby enhancing prediction accuracy and reliability. By constructing a predictive tool based on explainable deep learning models, the investigators will better assess the association between the use of calcineurin inhibitors and AKI, explore targeted prevention strategies, and offer more precise predictions and intervention guidance to clinicians. Additionally, this research has significant socio-economic benefits and application potential. By reducing the incidence of AKI, the investigators can lower patient hospitalization duration and re-treatment costs, conserve medical resources, and improve patient quality of life. Preventive healthcare not only alleviates the physical and psychological burden on patients but also reduces the strain on the healthcare system, enhances healthcare efficiency, and promotes the rational allocation of medical resources.

Enrollment

1,200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Use of tacrolimus during hospitalization, with standardized therapeutic drug monitoring
  • Age of 18 years or older at the time of admission
  • Length of hospital stay ≥ hours
  • At least two serum creatinine level tests conducted during the hospital stay

Exclusion criteria

  • Stage 5 chronic kidney disease prior to admission
  • Incomplete clinical data
  • Serum creatinine levels consistently below 40 mmol/L during hospitalization

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems